Volume : 09, Issue : 05, May – 2022
Title:
03.REGULATORY APPROVAL PROCESS FOR SPUTNIK VACCINE APPROVAL IN INDIA
Authors :
Mohamad Ali Ahamad*, Gottipati Meghana, Sampathi Mahi Varshini, M. V. Nagabhushanam, Y. Ratna Sindhu, Brahmaiah Bonthagarala, G. Ramakrishna, Santosh Kumar Ch
Abstract :
The human world and man lifestyle was completely shaken and changed with the outbreak of novel corona virus (Covid-19) which begun in Wuhan, China in Dec 2019 was declared a pandemic by World Health Organization on 11 March 2020. To stop this uncontrollable and life-threatening virus scientists from all over the world started research to find a solution or cure to this evil virus and to protect mankind. In this process vaccine was proved to be a better solution to put a check to this pandemic virus. In this article we wanted to brush up your knowledge on covid-19 and various vaccines in market and to educate the regulatory process for approval of sputnik V in India.
Keywords: Sputnik V, pandemic virus, Vaccines, World Health Organization, covid-19, Regulatory Approval Process.
Cite This Article:
Please cite this article in press Mohamad Ali Ahamad et al, Regulatory Approval Process For Sputnik Vaccine Approval In India., Indo Am. J. P. Sci, 2022; 09(5).,
Number of Downloads : 10
References:
1. Sohrabi, C.; Alsafi, Z.; O’Neill, N.; Khan, M.; Kerwan, A.; Al-Jabir, A.; Iosifidis, C.; Agha, R. World Health Organization declares global emergency: A review of the 2019 novel corona virus (COVID-19). Int. J. Surg. 2020, 76, 71–76. [CrossRef]
2. Li, R.; Pei, S.; Chen, B. Substantial undocumented infection facilitates the rapid dissemination of novel corona virus (SARS-CoV2). Science 2020, 368, 489–493. [CrossRef] [PubMed]
3. Elbek, O. COVID-19 Outbreak and Turkey. Turk. Thorac. J. 2020, 21, 215. [PubMed]
4. Kumar, S.U.; Kumar, D.T.; Christopher, B.P.; Doss, C. The rise and impact of COVID-19 in India. Front. Med. 2020, 7, 250. [CrossRef] [PubMed]
5. Susanto, A.P.; Findyartini, A.; Taher, A.; Susilaradeya, D.P.; Ariawan, I.; Dartanto, T.; Takwin, B.; Prasodjo, I.B.; Yusuf, P.A.; Sudarmono, P.P.; et al. COVID-19 in Indonesia: Challenges and Multidisciplinary Perspectives for a Safe and Productive New Normal. Acta Med. Indones. 2020, 52, 423–430.
6. Kafieh, R.; Arian, R.; Saeedizadeh, N.; Amini, Z.; Serej, N.D.; Minaee, S.; Yadav, S.K.; Vaezi, A.; Rezaei, N.; Javanmard, S.H. COVID-19 in Iran: Forecasting Pandemic Using Deep Learning. Comput. Math. Methods Med. 2021, 2021, 6927985. [CrossRef]
7. OECD/WHO. The impact of the COVID-19 outbreak on Asia-Pacific health systems. In Health at a Glance: Asia/Pacific 2020: Measuring Progress Towards Universal Health Coverage; OECD Publishing: Paris, France, 2020. [CrossRef]
8. 8. Triggle, C.R.; Bansal, D.; Farag, E.A.B.A.; Ding, H.; Sultan, A.A. COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. mSphere 2020, 5, 5. [CrossRef]
9. Cheng, H.-Y.; Huang, A.S.-E. Proactive and blended approach for COVID-19 control in Taiwan. Biochem. Biophys. Res. Commun. 2021, 538, 238–243. [CrossRef] [PubMed]
10. Chang, I.W.J. Taiwan’s Model for Combating COVID-19: A Small Island with Big Data. In COVID-19 in the Middle East and Asia: Impacts and Responses; Ministry of Health and Welfare: Taipei, Taiwan, 2020.
11. Agoramoorthy, G.; Shieh, P. Control of the COVID-19: A Successful Model of a Small Island. Interciencia 2020, 45, 174. Vaccines 2021, 9, 600 25 of 27
12. Yamamoto, N.; Bauer, G. Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation. Med. Hypotheses 2020, 144, 110160. [CrossRef] [PubMed]
13. Omer, S.B.; Malani, P.; Del Rio, C. The COVID-19 pandemic in the US: A clinical update. JAMA 2020, 323, 1767–1768. [CrossRef] [PubMed]
14. Haug, N.; Geyrhofer, L.; Londei, A.; Dervic, E.; Desvars-Larrive, A.; Loreto, V.; Pinior, B.; Thurner, S.; Klimek, P. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat. Hum. Behav. 2020, 4, 1303–1312. [CrossRef]
15. Forni, G.; Mantovani, A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ. 2021, 28, 626–639. [CrossRef]
16. Chakraborty, C.; Agoramoorthy, G. India’s cost-effective COVID-19 vaccine development initiatives. Vaccine 2020, 38, 7883–7884. [CrossRef]
17. Vaidyanathan, G. India will supply corona virus vaccines to the world—Will its people benefit? Nat. Cell Biol. 2020, 585, 167–168. [CrossRef] [PubMed]
18. Thiagarajan, K. Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. BMJ 2021, 372, n196. [CrossRef] [PubMed]
19. Cyranoski, D. China’s corona virus vaccines are leaping ahead-but face challenges as virus wanes. Nature 2020, 584, 17–18. [CrossRef] [PubMed]
20. Xiong, C.; Jiang, L.; Chen, Y.; Jiang, Q. Evolution and variation of 2019-novel corona virus. Biorxiv 2020. [CrossRef]
21. Bhattacharya, M.; Sharma, A.R.; Patra, P.; Ghosh, P.; Sharma, G.; Patra, B.C.; Lee, S.S.; Chakraborty, C. Development of epitopebased peptide vaccine against novel corona virus 2019 (SARS-COV-2): Immunoinformatics approach. J. Med. Virol. 2020, 92, 618–631. [CrossRef] [PubMed]
22. Chakraborty, C.; Sharma, A.R.; Bhattacharya, M.; Sharma, G.; Saha, R.P.; Lee, S.-S. Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic. Immune Netw. 2021, 21, e5. [CrossRef] [PubMed]
23. Cohen, J. With record-setting speed, vaccinemakers take their first shots at the new corona virus. Science 2020, 31. [CrossRef]
24. Thanh Le, T.; Andreadakis, Z.; Kumar, A.; Gómez Román, R.; Tollefsen, S.; Saville, M.; Mayhew, S. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020, 19, 305–306. [CrossRef] [PubMed]
25. Le, T.T.; Cramer, J.P.; Chen, R.; Mayhew, S. Evolution of the COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020, 19, 667–668. [CrossRef]
26. Gates, B. Responding to Covid-19—A once-in-a-century pandemic? N. Engl. J. Med. 2020, 382, 1677–1679. [CrossRef] [PubMed]
27. Nuismer, S.L.; May, R.; Basinski, A.; Remien, C.H. Controlling epidemics with transmissible vaccines. PLoS ONE 2018, 13, e0196978. [CrossRef] [PubMed]
28. Greenwood, B. The contribution of vaccination to global health: Past, present and future. Philos. Trans. R. Soc. B Biol. Sci. 2014, 369, 20130433. [CrossRef] [PubMed]
29. Lahariya, C. A brief history of vaccines & vaccination in India. Indian J. Med. Res. 2014, 139, 491–511. [PubMed]
30. Shearer, F.M.; Moyes, C.; Pigott, D.M.; Brady, O.J.; Marinho, F.; Deshpande, A.; Longbottom, J.; Browne, A.J.; Kraemer, M.U.G.; O’Reilly, K.; et al. Global yellow fever vaccination coverage from 1970 to 2016: An adjusted retrospective analysis. Lancet Infect. Dis. 2017, 17, 1209–1217. [CrossRef]
31. Ruck, D.J.; Bentley, R.A.; Borycz, J. Early warning of vulnerable counties in a pandemic using socio-economic variables. Econ. Hum. Biol. 2021, 41, 100988. [CrossRef] [PubMed]
32. Painter, E.M.; Ussery, E.N.; Patel, A.; Hughes, M.M.; Zell, E.R.; Moulia, D.L.; Scharf, L.G.; Lynch, M.; Ritchey, M.D.; Toblin, R.L. Demographic characteristics of persons vaccinated during the first month of the COVID-19 vaccination program—United States, 14 December 2020–14 January 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 174. [CrossRef]
33. 33.Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in “BRICS” Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 20-39.
34. 34.Brahmaiah Bonthagarala, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic Goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, Issue 6 volume 6, November-December 2016, 144-157.
35. 35.Brahmaiah Bonthagarala, Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, Issue 6, Vol. 6 (November-December 2016), 1-19.
36. 36.Brahmaiah Bonthagarala, Nanomedicine Clinical Use, Regulatory And Toxicology Issues In Europe, Journal of Drug Delivery and Therapeutics, 2019; 9(4-s):846-848.